Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries; thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Strategic Expansion | Stryker's acquisition of Inari Medical for $4.9 billion positions the company for growth in the rapidly expanding peripheral vascular market |
Robotic Revolution | Explore Stryker's market leadership in surgical robotics, with record adoption of its Mako system driving significant market share gains in orthopedics |
Financial Fortitude | Delve into Stryker's robust financial performance, with 10.76% revenue growth and a "GREAT" financial health score, despite challenges like tariff headwinds |
Analyst Optimism | Discover why analysts are bullish on Stryker, with price targets ranging from $420 to $450, reflecting confidence in the company's growth strategy |
Metrics to compare | SYK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYKPeersSector | |
---|---|---|---|---|
P/E Ratio | 50.2x | −6.9x | −0.5x | |
PEG Ratio | −3.24 | 0.26 | 0.00 | |
Price/Book | 6.9x | 2.4x | 2.6x | |
Price / LTM Sales | 6.2x | 2.9x | 3.0x | |
Upside (Analyst Target) | 15.8% | 54.4% | 52.6% | |
Fair Value Upside | Unlock | −1.8% | 8.7% | Unlock |